Clovis Oncology May 4, 2022 Clovis Oncology's Q1 Rubraca Sales Fall 10 Percent Apr 1, 2022 In Brief This Week:Â Taiho Oncology, PamGene, Mursla, Autolus Therapeutics, Clovis Oncology Mar 16, 2022 Clovis Oncology, Evergreen Theragnostics Developing Actinium-225-Labeled Radionuclide Feb 23, 2022 Clovis Oncology's Rubraca Revenues Decline 16 Percent Jan 12, 2022 Clovis Announces Preliminary Q4 Financials; Provides Updates on Rubraca, Radionuclide Programs Nov 3, 2021 Clovis' Q3 Rubraca Sales Drop 2 Percent Aug 4, 2021 Clovis Oncology's Q2 Rubraca Sales Dip 8 Percent Jun 23, 2021 Clovis Oncology Begins Study of FAP-2286 Targeted Imaging Agent, Radionuclide Therapy May 11, 2021 Clovis' Rubraca Benefits BRCA1/2, PALB2-Mutated Pancreatic Cancer Patients as Maintenance Therapy Premium Mar 19, 2021 In Brief This Week: Merck, Clovis Oncology, Grail, GenomOncology, Veracyte, Amoy Diagnostics Jan 13, 2021 JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More Oct 27, 2020 FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies Jun 4, 2020 PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications Premium May 15, 2020 Clovis Oncology's Rubraca Gets FDA Approval for BRCA-Mutated, Difficult-to-Treat Prostate Cancer Jan 15, 2020 FDA Accepts Clovis Oncology's Supplemental Drug Application for Rubraca in Advanced Prostate Cancer Apr 2, 2019 Treatment With Less Toxic Rubraca in Molecularly-Defined Pancreatic Cancer Subset Proposed at AACR Premium Breaking News In Brief This Week: Gilead Sciences, Arcus Biosciences, Verismo Therapeutics, Caris Life Sciences Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round
